These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 20824397

  • 1. Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer.
    Kaira K, Endo M, Asakura K, Tsuya A, Nakamura Y, Naito T, Murakami H, Takahashi T, Yamamoto N.
    Ann Nucl Med; 2010 Dec; 24(10):697-705. PubMed ID: 20824397
    [Abstract] [Full Text] [Related]

  • 2. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer.
    Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, Ishizuka T, Kanai Y, Mori M, Endo K.
    J Nucl Med; 2009 Nov; 50(11):1770-6. PubMed ID: 19837768
    [Abstract] [Full Text] [Related]

  • 3. Large decreases in standardized uptake values after definitive radiation are associated with better survival of patients with locally advanced non-small cell lung cancer.
    Lopez Guerra JL, Gladish G, Komaki R, Gomez D, Zhuang Y, Liao Z.
    J Nucl Med; 2012 Feb; 53(2):225-33. PubMed ID: 22241911
    [Abstract] [Full Text] [Related]

  • 4. 18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer.
    Zhang ZJ, Chen JH, Meng L, Du JJ, Zhang L, Liu Y, Dai HH.
    Chin Med J (Engl); 2007 Jan 20; 120(2):125-31. PubMed ID: 17335654
    [Abstract] [Full Text] [Related]

  • 5. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ, Stephans KL, Reddy CA, Djemil T, Srinivas SM, Videtic GM.
    Int J Radiat Oncol Biol Phys; 2010 Nov 15; 78(4):1033-9. PubMed ID: 20472359
    [Abstract] [Full Text] [Related]

  • 6. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
    Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE, Patz EF.
    J Clin Oncol; 2008 Mar 20; 26(9):1459-64. PubMed ID: 18349396
    [Abstract] [Full Text] [Related]

  • 7. Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLC.
    Bahce I, Vos CG, Dickhoff C, Hartemink KJ, Dahele M, Smit EF, Boellaard R, Hoekstra OS, Thunnissen E.
    Lung Cancer; 2014 Aug 20; 85(2):205-12. PubMed ID: 24854401
    [Abstract] [Full Text] [Related]

  • 8. Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases.
    Al-Sarraf N, Gately K, Lucey J, Aziz R, Doddakula K, Wilson L, McGovern E, Young V.
    Eur J Cardiothorac Surg; 2008 Oct 20; 34(4):892-7. PubMed ID: 18722132
    [Abstract] [Full Text] [Related]

  • 9. Ratio of positron emission tomography uptake to tumor size in surgically resected non-small cell lung cancer.
    Stiles BM, Nasar A, Mirza F, Paul S, Lee PC, Port JL, McGraw TE, Altorki NK.
    Ann Thorac Surg; 2013 Feb 20; 95(2):397-403; discussion 404. PubMed ID: 23000262
    [Abstract] [Full Text] [Related]

  • 10. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
    Bollineni VR, Widder J, Pruim J, Langendijk JA, Wiegman EM.
    Int J Radiat Oncol Biol Phys; 2012 Jul 15; 83(4):e551-5. PubMed ID: 22417800
    [Abstract] [Full Text] [Related]

  • 11. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D, Scheffler M, Zander T, Nogova L, Lammertsma AA, Boellaard R, Neumaier B, Ullrich RT, Holstein A, Dietlein M, Wolf J, Kobe C.
    J Nucl Med; 2011 Dec 15; 52(12):1871-7. PubMed ID: 22065872
    [Abstract] [Full Text] [Related]

  • 12. Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
    Shimizu K, Okita R, Saisho S, Yukawa T, Maeda A, Nojima Y, Nakata M.
    Ann Nucl Med; 2015 Dec 15; 29(10):854-60. PubMed ID: 26254228
    [Abstract] [Full Text] [Related]

  • 13. Predictive value of 18F-fluorodeoxyglucose uptake by positron emission tomography for non-small cell lung cancer patients treated with radical radiotherapy.
    Ikushima H, Dong L, Erasmus J, Allen P, McAleer MF, Zhuang Y, Sasaki R, Komaki R.
    J Radiat Res; 2010 Dec 15; 51(4):465-71. PubMed ID: 20508373
    [Abstract] [Full Text] [Related]

  • 14. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.
    Dooms C, Verbeken E, Stroobants S, Nackaerts K, De Leyn P, Vansteenkiste J.
    J Clin Oncol; 2008 Mar 01; 26(7):1128-34. PubMed ID: 18309948
    [Abstract] [Full Text] [Related]

  • 15. Risk factors for predicting the occult nodal metastasis in T1-2N0M0 NSCLC patients staged by PET/CT: potential value in the clinic.
    Li L, Ren S, Zhang Y, Guan Y, Zhao J, Liu J, Wang Q, Chen G, Chen H, Xiang J, Fu X.
    Lung Cancer; 2013 Aug 01; 81(2):213-7. PubMed ID: 23664030
    [Abstract] [Full Text] [Related]

  • 16. Limited predictive value of dual-time-point F-18 FDG PET/CT for evaluation of pathologic N1 status in NSCLC patients.
    Kim SJ, Kim YK, Kim IJ, Kim YD, Lee MK.
    Clin Nucl Med; 2011 Jun 01; 36(6):434-9. PubMed ID: 21552019
    [Abstract] [Full Text] [Related]

  • 17. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection.
    Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, Rusch V.
    J Clin Oncol; 2004 Aug 15; 22(16):3255-60. PubMed ID: 15310769
    [Abstract] [Full Text] [Related]

  • 18. Risk factors for mediastinal lymph node metastasis in non-small-cell lung cancer by PET/CT.
    Xu ZQ, Xie LJ, Fan W, Duan XB, Cheng MH.
    Nucl Med Commun; 2014 May 15; 35(5):466-71. PubMed ID: 24535381
    [Abstract] [Full Text] [Related]

  • 19. [Prognostic value of (18)F-fluorodeoxyglucose uptake in patients with non-small cell lung cancer treated by concurrent chemoradiotherapy].
    Zhang HQ, Yu JM, Meng X, Yue JB, Feng R, Ma L.
    Zhonghua Zhong Liu Za Zhi; 2010 Aug 15; 32(8):603-6. PubMed ID: 21122413
    [Abstract] [Full Text] [Related]

  • 20. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer.
    Park SY, Cho A, Yu WS, Lee CY, Lee JG, Kim DJ, Chung KY.
    J Nucl Med; 2015 Jan 15; 56(1):45-9. PubMed ID: 25525185
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.